PeppiLibrary

Cognitive

Davunetide peptide reference

Eight-AA fragment of ADNP. Microtubule-stabilising and neuroprotective.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Davunetide notes
Default dose label15 mg
Preferred routeIntranasal
Frequency label1–2× daily
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Multiple Phase 2/3 trials; failed primary endpoints in PSP and schizophrenia

Investigational / research chemical

Route map

How records are usually labeled

1 Intranasal
2 SubQ

Alternate nostrils.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C, use within 14–30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 50 mg vial
Dose 15 mg
Route Intranasal
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Davunetide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Davunetide is a synthetic 8-amino-acid fragment of activity-dependent neuroprotective protein (ADNP). It promotes microtubule stabilisation and protects neurons against various stressors. Phase 3 trials in progressive supranuclear palsy (PSP) and schizophrenia cognition failed primary endpoints in 2012, but the peptide remains under investigation in other neurodegeneration contexts.

Also known as: NAP, AL-108, NAPVSIPQ.

Tauopathy research (PSP, Alzheimer's)Schizophrenia cognition researchNeuroprotection adjunct

Mechanism and timing snapshot

Stabilises microtubules through interaction with end-binding proteins (EB1/EB3). Protects against tau pathology, oxidative stress, and excitotoxic damage.

Onset label15 min
Catalog onset field, when available.
Half-life label30 min
Plasma half-life short; intranasal administration provides direct CNS uptake
Duration label8 hr
Catalog duration field, when available.
intranasal Reaches CNS via olfactory route
subQ High systemic, limited CNS
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose15 mg
Catalog dose range5 mg - 30 mg
Default routeIntranasal
Frequency label1–2× daily
Best time labelMorning and/or early afternoon.
Food noteNone.

Catalog protocol note

Trial dose: 15 mg or 30 mg intranasally daily.

Routes and site notes

Available route labelsIntranasal, SubQ
Preferred route labelIntranasal
Common site labelsBoth nostrils, alternating
Site rotation noteAlternate nostrils.

Chemistry

SequenceAsn-Ala-Pro-Val-Ser-Ile-Pro-Gln (NAPVSIPQ)
Amino acids8
Molecular formulaC37H64N10O12
Molecular weight824.96 Da

Vial, reconstitution, and storage

Supply formLyophilized powder; commercial trials used pre-formulated nasal spray
Typical vial size50 mg
DiluentBacteriostatic water or saline
Diluent volume5 mL
Concentration note50 mg in 5 mL → 1.5 mL = 15 mg per dose (depends on sprayer).
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C, use within 14–30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Mild nasal irritation
  • Headache
  • Mild fatigue

Contraindications and warnings

  • Pregnancy
  • Phase 3 endpoint failures in PSP and schizophrenia cognition (2012); not approved.

Other considerations

  • Microtubule-stabilising mechanism is mechanistically distinct from BDNF-targeting nootropics.
  • Phase 3 failures temper but don't eliminate research interest.
  • Subjective effects are subtle compared to typical nootropic stimulants.

Evidence and regulatory context

Evidence levelMultiple Phase 2/3 trials; failed primary endpoints in PSP and schizophrenia
FDA approvedNo
Regulatory statusInvestigational / research chemical
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteNot listed
Typical cycle label4–12
Typical break label4
Cycle guidanceCourse-based; chronic continuous use uncharacterised.

Tracking tips

  • Set realistic expectations — Phase 3 endpoint failures matter.
  • Mechanism (microtubule stabilisation) is distinct from BDNF-targeting nootropics.
  • Best as a research curiosity rather than a daily nootropic.

References

Track it in Peppi

Keep Davunetide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Davunetide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Davunetide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Davunetide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026